Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype.
about
Molecular composition and ultrastructure of the caveolar coat complexCharacterization of the molecular architecture of human caveolin-3 and interaction with the skeletal muscle ryanodine receptorMicroRNA dysregulation in diabetic ischemic heart failure patientsEndothelial transmigration by Trypanosoma cruziPTRF/Cavin-1 Deficiency Causes Cardiac Dysfunction Accompanied by Cardiomyocyte Hypertrophy and Cardiac FibrosisLipid modulation of skeletal muscle mass and functionCurrent understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas diseaseCaveolin-1 abolishment attenuates the myogenic response in murine cerebral arteriesCaveolin-1-dependent beta1 integrin endocytosis is a critical regulator of fibronectin turnoverMaternal nutrient restriction alters gene expression in the ovine fetal heart.Changes in membrane cholesterol affect caveolin-1 localization and ICC-pacing in mouse jejunum.Colocalization between caveolin isoforms in the intestinal smooth muscle and interstitial cells of Cajal of the Cav1(+/+) and Cav1 (-/-) mouse.Matrix metalloproteinase-2, caveolins, focal adhesion kinase and c-Kit in cells of the mouse myocardiumClathrin-independent pathways of endocytosis.Mitochondria-localized caveolin in adaptation to cellular stress and injury.Fibronectin matrix turnover occurs through a caveolin-1-dependent process.Signaling epicenters: the role of caveolae and caveolins in volatile anesthetic induced cardiac protection.Role of caveolin 1 in AT1a receptor-mediated uptake of angiotensin II in the proximal tubule of the kidney.Palmitate diet-induced loss of cardiac caveolin-3: a novel mechanism for lipid-induced contractile dysfunction.Cavin1; a regulator of lung function and macrophage phenotype.Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance.Caveolae as organizers of pharmacologically relevant signal transduction molecules.Simultaneous expression of flotillin-1, flotillin-2, stomatin and caveolin-1 in non-small cell lung cancer and soft tissue sarcomasCholesterol removal from adult skeletal muscle impairs excitation-contraction coupling and aging reduces caveolin-3 and alters the expression of other triadic proteins.Caveolin-1alpha and -1beta perform nonredundant roles in early vertebrate developmentFunction of caveolae in Ca2+ entry and Ca2+-dependent signal transduction.Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.Telmisartan regresses left ventricular hypertrophy in caveolin-1-deficient mice.Epigenetic modifications of caveolae associated proteins in health and disease.Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease.Chagas heart disease: report on recent developments.Caveolae-associated signalling in smooth muscle.Insulin signaling in heart muscle: lessons from genetically engineered mouse models.Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization.Regulation of G protein-coupled receptor endocytosis by ARF6 GTP-binding proteins.Molecular Characterization of Caveolin-induced Membrane Curvature.Caveolins: targeting pro-survival signaling in the heart and brain.The R-spondin family of proteins: emerging regulators of WNT signaling.Recent developments in the interactions between caveolin and pathogens.Caveolin and β1-integrin coordinate angiotensinogen expression in cardiac myocytes
P2860
Q24323250-73E301A7-5751-462E-A6B6-1DABD7CB90F5Q24608212-5ACE0BA5-BDB4-468B-ACC8-776DD6894084Q24618462-C53C7E7E-1619-41E6-944A-4B878A9E5780Q27301348-E90650B3-E14C-45B6-8927-E49811302959Q27322991-954B3E32-CF13-47CE-B379-EBCDD2993ECBQ28073878-70F417D6-590A-4864-B2A1-8A0B821030AAQ28391025-BE6929CB-D29F-4763-90C6-5B8B6FAB68C7Q28507559-3689B157-4CC6-4062-A20C-ECF4D26F1149Q28574901-6AFF06BB-5CEB-485D-B8F6-FB68BD537496Q30831154-03D5BC18-75B7-4EDA-842D-EE50B370D769Q33198520-EB4B29D9-0492-4D90-9BD9-6BC2086CDA0AQ33230063-36065FD4-44CB-456F-8136-5E72CF95725AQ33304870-78F09710-2182-4A57-A6C7-4B4DEF9C5E53Q33653693-ADE6E990-C20F-4325-BC3C-7B6FC350F25FQ33729738-2065C25E-B2EA-4FEB-96C9-35ABB1D60B04Q33763861-08EB1A2F-B308-436B-8A7B-A920A2E82ED7Q33993790-BB20E188-0F15-4AE7-8F6B-67FD174AFDD7Q34355891-E3D0D3AA-042C-449A-B352-9624C18E5CC2Q34667984-8307080F-7A51-4ED2-950E-4A0A1799AC5DQ34698258-B08654EF-E97A-49D8-B6E4-462A9E01E47AQ34847724-42970F5B-B5D6-4FA1-A7A8-B4D354FFB955Q34877306-320027E4-8AC1-4453-8CAA-12CE1D5B5210Q35095704-617E46AF-EDC8-4C37-9436-77A3CFEB4025Q35356113-C96EE38D-1819-4247-B171-51FBB163EBA1Q35569835-480C04D5-080D-48CB-AD05-F31DD3BCD50FQ35583679-F1C311CF-7F57-41F3-8459-D1DB8113EAD7Q35625960-B07976FA-B506-41B8-939B-239170A87096Q35642421-40022ADE-E0CD-49ED-AC9B-653EBD4FA818Q35674847-3CBA6379-36CF-411D-AD70-D70260790F04Q35723460-3211F2AC-C8BF-4162-8648-5E35CF08BC76Q35745413-AA3492AD-328B-4107-9E92-25D66BEB3C56Q35815016-1E7CC27B-285B-4D44-95AF-EAF87393DF2EQ35940001-104AC9E1-CEBF-4C79-AD51-2FA2B8172AA0Q35968549-A3325CAE-30D1-408B-8FCD-8158B38618CFQ36021503-F1A458EE-3B32-4C71-86D2-BE7A0E8F9529Q36139854-62866882-AF8F-4D9F-9CD3-529FE9FAAC75Q36298845-1AAA6A47-202C-4684-9DE2-41B6BAA3AF6AQ36392765-C01E5981-990E-4CD7-99DE-C766DB935378Q36586691-CE212E8E-D7DB-4A81-99EB-0549E740FF04Q36617132-A598E0B1-4CD9-4D9C-98BF-8433D4CC94F9
P2860
Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Caveolin-1/3 double-knockout m ...... ere cardiomyopathic phenotype.
@ast
Caveolin-1/3 double-knockout m ...... ere cardiomyopathic phenotype.
@en
type
label
Caveolin-1/3 double-knockout m ...... ere cardiomyopathic phenotype.
@ast
Caveolin-1/3 double-knockout m ...... ere cardiomyopathic phenotype.
@en
prefLabel
Caveolin-1/3 double-knockout m ...... ere cardiomyopathic phenotype.
@ast
Caveolin-1/3 double-knockout m ...... ere cardiomyopathic phenotype.
@en
P2093
P2860
P50
P1476
Caveolin-1/3 double-knockout m ...... vere cardiomyopathic phenotype
@en
P2093
Alex W Cohen
Babak Razani
Baiyu Tang
David S Park
Jamshid Shirani
Linda A Jelicks
Louis M Weiss
Madhulika Chandra
Scott E Woodman
Stephen M Factor
P2860
P304
P356
10.1016/S0002-9440(10)61168-6
P407
P577
2002-06-01T00:00:00Z